CheckMan Stock Market Overview

BioMarin Pharmaceutical Inc.'s primary endpoint was met in the phase 3 Pegasus study, which used Palynziq for the treatment of adolescent patients ages 12 - 17 with phenylketonuria. The company is set to file regulatory applications to expand the label of Palynziq for phenylketonuria patients in both the U.S. and European territories in 2nd half of 2025. The global phenylketonuria market size is estimated to reach $2.02 billion by 2032.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai LifeSciences To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , April 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc.  ("Maravai" or the "Company") (NASDAQ: MRVI) and reminds investors of the May 5, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Combining performance, design, and feel-good energy, this new brand campaign invites consumers to turn cleaning into a feel-good experience ST. PAUL, Minn.

Waste Management, Inc. (NYSE:WM ) 11th Annual Waste & Environmental Services Symposium April 3, 2025 12:15 PM ET Company Participants Ed Egl - IR Conference Call Participants Tony Bancroft - Gabelli Funds Tony Bancroft I'd like to do reintroduce, Ed Egl, Head of Investor Relations at WM. WM is based in Houston, Texas.

Investors can contact the law firm at no cost to learn more about recovering their losses

Citigroup is undervalued, trading at 0.79x tangible book value, presenting a potential long-term investment if Jane Fraser's restructuring plan succeeds. Despite weak sentiment and regulatory issues, Citi's EPS growth and realistic RoTE targets show promise for future profitability. Economic risks include potential loan defaults and fluctuating net interest income, but stable rates and restructuring could improve margins.

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Atkore Inc. (NYSE:ATKR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atkore-inc-lawsuit-submission-form?prid=140804&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your The Trade Desk, Inc. (NASDAQ:TTD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-trade-desk-inc-lawsuit-submission-form?prid=140806&wire=1 or contact Joseph E. Levi, Esq.

HURLBURT FIELD, Fla.--(BUSINESS WIRE)--L3Harris Technologies (NYSE: LHX) and Air Tractor have delivered the first missionized OA-1K Skyraider II aircraft to support U.S. Air Force Special Operations Command. The Skyraider II will help ensure special operations personnel can meet the needs of the National Defense Strategy and the joint force. Special Operations Forces (SOF) will fly Skyraider II in various missions and will deliver close air support, precision strike, and armed intelligence, sur.

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=140799&wire=1 or contact Joseph E. Levi, Esq.